Continuous Renal Replacement Therapy

October 11, 2007

Gregory M. Susla, Pharm.D., F.C.C.M.
Associate Director, Medical Information
MedImmune, Inc.
Gaithersburg, MD

Definition of Terms

* SCUF - Slow Continuous Ultrafiltration
* CAVH - Continuous Arteriovenous Hemofiltration
* CAVH-D - Continuous Arteriovenous Hemofiltration with Dialysis
* CVVH - Continuous Venovenous Hemofiltration
* CVVH-D - Continuous Venovenous Hemofiltration with Dialysis

Indications for Continuous Renal Replacement Therapy

* Remove excess fluid because of fluid overload
* Clinical need to administer fluid to someone who is oliguric
  - Nutrition solution
  - Antibiotics
  - Vasoactive substances
  - Blood products
  - Other parenteral medications

Advantages of Continuous Renal Replacement Therapy

* Hemodynamic stability
  - Avoid hypotension complicating hemodialysis
  - Avoid swings in intravascular volume
* Easy to regulate fluid volume
  - Volume removal is continuous
  - Adjust fluid removal rate on an hourly basis
* Customize replacement solutions
* Lack of need of specialized support staff

Disadvantages of Continuous Renal Replacement Therapy

* Lack of rapid fluid and solute removal
  - GFR equivalent of 5 - 20 ml/min
  - Limited role in overdose setting
* Filter clotting
  - Take down the entire system

Basic Principles

* Blood passes down one side of a highly permeable membrane
* Water and solute pass across the membrane
  - Solutes up to 20,000 daltons
    * Drugs & electrolytes
* Infuse replacement solution with physiologic concentrations of electrolytes

Anatomy of a Hemofilter





Outside the Fiber
(effluent)
Inside the Fiber
(blood)

Basic Principles

* Hemofiltration
  - Convection based on a pressure gradient
  - ‘Transmembrane pressure gradient’
    * Difference between plasma oncotic pressure and hydrostatic pressure
* Dialysis
  - Diffusion based on a concentration gradient

CVVH

Continuous Veno-Venous Hemofiltration



CVVH
Continuous VV Hemofiltration

* Primary therapeutic goal:
  - Convective solute removal
  - Management of intravascular volume
* Blood Flow rate = 10 - 180 ml/min
* UF rate ranges 6 - 50 L/24 h (> 500 ml/h)
* Requires replacement solution to drive convection
* No dialysate

CVVH Performance



Continuous venovenous hemofiltration
“In vitro” ultrafiltration with blood (post-dilution)
(values ± 15%) (Bovine blood at 37° C, Hct 32%, Cp 60g/l)

CVVHDF

Continuous Veno-Venous Hemodiafiltration



CVVHDF
Continuous VV Hemodiafiltration

* Primary therapeutic goal:
  - Solute removal by diffusion and convection
  - Management of intravascular volume
* Blood Flow rate = 10 - 180ml/min
* Combines CVVH and CVVHD therapies
* UF rate ranges 12 - 24 L/24h (> 500 ml/h)
* Dialysate Flow rate = 15 - 45 ml/min (~1 - 3 L/h)
* Uses both dialysate (1 L/h) and replacement fluid (500 ml/h)

Pharmacokinetics of Continuous Renal Replacement Therapy

Basic Principles

* Extracorporeal clearance (Cl_{EC}) is usually considered clinically significant only if its contribution to total body clearance exceeds 25 - 30%

$$Fr_{EC} = Cl_{EC} / \ Cl_{EC} + Cl_{R} + Cl_{NR}$$

* Not relevant for drugs with high non-renal clearance
* Only drug not bound to plasma proteins can be removed by extracorporeal procedures

Determinants of Drug Removal by CRRT

* Drug	Same as hemodialysis but increased MW range
* Membrane	Permeability Sieving Coefficient
* Renal replacement technique	Convection ± diffusion Cl Flow rates Blood, Dialysate, UF Duration of CRRT

Sieving Coefficient (S)

* The capacity of a drug to pass through the hemofilter membrane

$$S = C_{uf} / C_p$$

C_{uf} = drug concentration in the ultrafiltrate

C_p = drug concentration in the plasma

S = 1 Solute freely passes through the filter

S = 0 Solute does not pass through the filter

$$CL_{HF} = Q_f \times S$$

Determinants of Sieving Coefficient

* Protein binding
  - Only unbound drug passes through the filter
    * Protein binding changes in critical illness
* Drug membrane interactions
  - Not clinically relevant
* Adsorption of proteins and blood products onto filter
  - Related to filter age
  - Decreased efficiency of filter

Relationship Between Free Fraction (*fu*) and Sieving Coefficient (*SC*)



Dialysate Saturation (S_d)

* Countercurrent dialysate flow (10 - 30 ml/min) is always less than blood flow (100 - 200 ml/min)
* Allows complete equilibrium between blood serum and dialysate
* Dialysate leaving filter will be 100% saturated with easily diffusible solutes
* Diffusive clearance will equal dialysate flow

Dialysate Saturation (S_d)

$$S_d = C_d / C_p$$

C_d = drug concentration in the dialysate

C_p = drug concentration in the plasma

* Decreasing dialysate saturation
  - Increasing molecular weight
    * Decreases speed of diffusion
  - Increasing dialysate flow rate
    * Decreases time available for diffusion

$$Cl_{HD} = Q_d \times S_d$$

CVVHDF Clearance



Continuous venovenous hemofiltration - post dilution

QB = 150 ml/min - QD = 2000 ml/h (in vitro saline)

Extracorporeal Clearance

* Hemofiltration clearance ($Cl_{HF} = Q_f \times S$)
  - Q_f = Ultrafiltration rate
  - S = Seiving coefficient
* Hemodialysis clearance ($Cl_{HD} = Q_d \times S_d$)
  - Q_d = Dialysate flow rate
  - S_d = Dialysate saturation
* Hemodialfiltration clearance

$$Cl_{HDF} = (Q_f \times S) + (Q_d \times S_d)$$

Case History

* AP 36yo HM s/p BMT for aplastic anemia
* Admitted to ICU for management of acute renal failure
* CVVH-D initiated for management of uremia
* ICU course complicated by pulmonary failure failure requiring mechanical ventilation, liver failure secondary to GVHD and VOD, and sepsis

Case History
Antibiotic Management on CRRT

* Gentamicin 180 mg IV q24h
* Vancomycin 1 g IV q24h
* Dialysis rate 1000 ml/hour
  - 12 hour post gentamicin levels: 3 - 4 mg/L
  - 12 hour post vancomycin levels: 20 - 23 mg/L
* Dialysis rate increased to 1200 ml/hour
  - 12 hour post gentamicin levels: < 0.4 mg/L
  - 12 hour post vancomycin levels: < 4 mg/L

Dosage Adjustments in CRRT

* Will the drug be removed?
  - Pharmacokinetic parameters
    * Protein binding < 70 - 80%
      - Normal values may not apply to critically ill patients
    * Volume of distribution < 1 L/kg
    * Renal clearance > 35%
* How often do I dose the drug?
  - Hemofiltration: ‘GFR’ 10 - 20 ml/min
  - Hemofiltration with dialysis: ‘GFR’ 20 - 50 ml/min

Drug Removal During CRRT

* Recommendations not listed in PDR
* Limited to case reports or series of patients
* Different filter brands, sizes, flow rates
* Limited information in many reports
  - Rarely report % of dose removed
* Many journals will not publish case reports
* Artificial models and predictions have no clinical value

Dosage Adjustments in CRRT

* Loading doses
  - Do not need to be adjusted
  - Loading dose depends solely on volume of distribution
* Maintenance doses
  - Standard reference tables
  - Base on measured loses
  - Calculate maintenance dose multiplication factor (MDMF)

Dosage Adjustments in CRRT

* Frequent blood level determinations
  - Aminoglycosides, vancomycin
* Reference tables
  - Bennett's tables or the PDR recommendations require an approximation of patient's GFR
  - The CVVH ‘GFR’ is approximated by the ultrafiltrate rate (UFR), plus any residual renal clearance
  - Using Bennett's or the PDR’s tables, in most CVVH patients, drug dosing can be adjusted for a ‘GFR’ in the range of 10 to 50 ml/min

Supplemental Dose Based on Measured Plasma Level

$$\text{Dose}_{\text{Suppl}} = \left(C_{\text{target}} - C_{\text{measured}}\right) V_d$$

Adjusted Dose Based on Clearance Estimates

$$MDMF = \frac{CL_{EC} + CL_{R} + CL_{NR}}{CL_{R} + CL_{NR}}$$

COMPARISON OF DRUG REMOVAL BY INTERMITTENT HD AND CRRT

DRUG	$CL_R + CL_{NR}$ (mL/min)	*MDMF*	
		INTERMITTENT HEMODIALYSIS	CONTINUOUS RENAL REPLACEMENT
CEFTAZIDIME	11.2	1.6	2.2
CEFTRIAZONE	7.0	1.0	3.4
CIPROFLOXACIN	188	1.0	2.4
THEOPHYLLINE	57.4	1.1	1.4
VANCOMYCIN	6	3.9	4.9